| Description | Vantictumab (OMP-18R5), a fully human IgG2 monoclonal antibody, antagonizes Wnt pathway signaling through binding to FZD1/2/5/7/8 receptors. It is currently under investigation for the treatment of various cancers, including metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma [1] [2]. |
| Synonyms | OMP-18R5 |
| molecular weight | N/A |
| CAS | 1345009-45-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |